Grandfield & Dodd’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $365K | Hold |
1,667
| – | – | 0.02% | 161 |
|
2025
Q1 | $373K | Hold |
1,667
| – | – | 0.02% | 155 |
|
2024
Q4 | $546K | Hold |
1,667
| – | – | 0.03% | 138 |
|
2024
Q3 | $500K | Sell |
1,667
-351
| -17% | -$105K | 0.03% | 142 |
|
2024
Q2 | $665K | Hold |
2,018
| – | – | 0.04% | 123 |
|
2024
Q1 | $799K | Hold |
2,018
| – | – | 0.05% | 117 |
|
2023
Q4 | $711K | Hold |
2,018
| – | – | 0.05% | 119 |
|
2023
Q3 | $757K | Hold |
2,018
| – | – | 0.06% | 117 |
|
2023
Q2 | $772K | Hold |
2,018
| – | – | 0.05% | 119 |
|
2023
Q1 | $699K | Hold |
2,018
| – | – | 0.05% | 123 |
|
2022
Q4 | $475K | Hold |
2,018
| – | – | 0.03% | 131 |
|
2022
Q3 | $500K | Hold |
2,018
| – | – | 0.04% | 122 |
|
2022
Q2 | $610K | Hold |
2,018
| – | – | 0.05% | 123 |
|
2022
Q1 | $830K | Hold |
2,018
| – | – | 0.06% | 116 |
|
2021
Q4 | $950K | Hold |
2,018
| – | – | 0.06% | 107 |
|
2021
Q3 | $860K | Hold |
2,018
| – | – | 0.06% | 110 |
|
2021
Q2 | $720K | Hold |
2,018
| – | – | 0.05% | 116 |
|
2021
Q1 | $570K | Hold |
2,018
| – | – | 0.04% | 125 |
|
2020
Q4 | $570K | Hold |
2,018
| – | – | 0.04% | 121 |
|
2020
Q3 | $550K | Sell |
2,018
-70
| -3% | -$19.1K | 0.05% | 118 |
|
2020
Q2 | $470K | Hold |
2,088
| – | – | 0.05% | 124 |
|
2020
Q1 | $318K | Hold |
2,088
| – | – | 0.04% | 138 |
|
2019
Q4 | $314K | Hold |
2,088
| – | – | 0.03% | 150 |
|
2019
Q3 | $296K | Hold |
2,088
| – | – | 0.03% | 150 |
|
2019
Q2 | $261K | Hold |
2,088
| – | – | 0.03% | 158 |
|
2019
Q1 | $230K | Hold |
2,088
| – | – | 0.02% | 160 |
|
2018
Q4 | $205K | Hold |
2,088
| – | – | 0.02% | 163 |
|
2018
Q3 | $258K | Hold |
2,088
| – | – | 0.03% | 163 |
|
2018
Q2 | $207K | Buy |
+2,088
| New | +$207K | 0.02% | 175 |
|
2018
Q1 | – | Sell |
-2,088
| Closed | -$206K | – | 187 |
|
2017
Q4 | $206K | Hold |
2,088
| – | – | 0.02% | 181 |
|
2017
Q3 | $201K | Buy |
+2,088
| New | +$201K | 0.02% | 182 |
|